The Patent Finder

Terms ending in 2041

Valneva SE

Every in-force patent on Valneva SE's record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 11,684,669CpG-ADJUVANTED SARS-CoV-2 VIRUS VACCINE
In force
 · High confidence
Dynavax Technologies CorporationnIn forceHigh confidence
US 12,162,907A Subunit Vaccine for Treatment or Prevention of a Respiratory Tract Infection
In force
 · High confidence
Valneva SEIn forceHigh confidence
US 12,018,054Multivalent Ospa Polypeptides and Methods and Uses Relating Thereto
In force
 · High confidence
Valneva Austria GmbHIn forceHigh confidence
3 of 3 patents shown. Soonest term end first, then patent number.
2 of these are in force and held by Valneva SE.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited